70th anniversary of Hanoi's Liberation Day Vietnam - Asia 2023 Smart City Summit Hanoi celebrates 15 years of administrative boundary adjustment 12th Vietnam-France decentrialized cooperation conference 31st Sea Games - Vietnam 2021 Covid-19 Pandemic
Home / Investment / News
ADB, Imexpharm sign US$8-million loan to support generic medicine production in Vietnam
Hai Yen 20:22, 2020/12/15
The financing will support the company’s working capital needs to ensure ample supply of active pharmaceutical ingredients for essential generic medicine production.

The Asian Development Bank (ADB) signed an US$8 million loan with Imexpharm Corporation to help the company sustain its production of generic medicines despite global supply disruptions caused by the Covid-19 pandemic.

 Loan from ADB will help Imexpharm maintain production of generic pharmaceuticals. 

The financing will support the company’s working capital needs to ensure ample supply of active pharmaceutical ingredients for essential generic medicine production. Imexpharm’s operations and continued production of generic pharmaceuticals and their ensured availability in the market is integral in safeguarding the country’s health care during the pandemic.

Head of Health and Education Investments at ADB's Private Sector Operations Department Aniruddha Patil said Asia has witnessed disruptions across the pharmaceutical supply chain in 2020, including a shortage of active pharmaceutical ingredients.

“This project demonstrates ADB’s continued efforts to enhance health outcomes in Vietnam by encouraging the development and use of local generic medicines,” Mr. Aniruddha Patil. 

 

“We are pleased to be working with ADB,” said Imexpharm’s Chairman Nguyen Quoc Dinh. “The financing will improve our liquidity situation and ensure a consistent supply of affordable generic drugs to hospitals and pharmacies across Vietnam.”

This debt financing is part of ADB’s US$20 billion assistance announced on April 13 to help its developing members manage the pandemic.

Imexpharm was established in 1977 and initially incorporated in 1983 as the Dong Thap Pharmaceutical Union. The firm was transformed from a state-owned enterprise into a joint-stock company and renamed Imexpharm Corporation, and its shares were listed on the Ho Chi Minh Stock Exchange on December 4, 2006. As of September 30, 2020, Imexpharm had 1,252 employees, total assets of VND2.07 trillion (US$89.33 million) and 6 pharmaceutical manufacturing facilities.

RELATED NEWS
TAG: Vietnam ADB Imexpharm covid-19 coronavirus nCoV pandemic generic medicine production pharmaceutical
Other news
15:05, 2024/02/29
Thai bank acquires Vietnamese finance company
Thailand's fourth-largest bank has agreed to acquire all the equity of Home Credit Vietnam for US$865 million.
14:08, 2024/01/27
Vietnam appreciates support from int’l friends in nation-building: PM
The goal is to develop Vietnam's economy and become a regional powerhouse in Asia.
15:18, 2024/01/20
Vietnam, Hungary call for stronger economic ties
Leaders from both sides also reaffirmed their commitment to creating a "peace of mind" investment environment for investors.
12:53, 2024/01/13
Vietnam - Indonesia expand cooperation to include green growth, EV ecosystem
Both countries share a vision to become high-income countries by 2045.
10:54, 2024/01/03
Vietnam ready to absorb investment capital in semiconductor industry
The Vietnamese Government is formulating highly competitive policies to attract investment in the semiconductor industry.
20:08, 2023/12/23
India’s largest energy group eyes investment in Vietnam
Adani expects to invest in Vietnam's thermal power plants and participate in the development of both the renewable energy industry and key thermal energy projects.